Novel imatinib-sensitive PDGFRA activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease
Novel imatinib-sensitive PDGFRA activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease
The FIP1L1-PDGFRA fusion is seen in a fraction of cases with a presumptive diagnosis of hypereosinophilic syndrome (HES). However, since most HES patients lack FIP1L1-PDGFRA, we studied whether they harbor activating mutations of the PDGFRA gene. Sequencing of 87 FIP1L1-PDGFRA negative HES patients revealed several novel PDGFRA point mutations (R481G, L507P, I562M, H570R, H650Q, N659S, L705P, R748G, and Y849S). When cloned into 32D cells, N659S and Y849S and, upon selection for high expressors, also H650Q and R748G mutants induced growth factor-independent proliferation, clonogenic growth, and constitutive phosphorylation of PDGFRA and STAT5. Imatinib antagonized STAT5 phosphorylation. Mutations involving positions 659 and 849 had been shown previously to possess transforming potential in gastrointestinal stromal tumors. Since H650Q and R748G mutants possessed only weak transforming activity, we injected 32D cells harboring these mutants or FIP1L1-PDGFRA into mice and found that they induced a leukemia-like disease. Oral imatinib treatment significantly decreased leukemic growth in vivo and prolonged survival. In conclusion, our data provide evidence that imatinib-sensitive PDGFRA point mutations play an important role in the pathogenesis of HES and we propose that more research should be performed to further define the frequency and treatment response of PDGFRA mutations in FIP1L1-PDGFRA negative HES patients
2935-2943
Elling, Christian
51a03004-8d0b-4f55-addf-54451e648ce0
Erben, Phillipp
ab2de2e7-98f4-495f-add1-00b7e0e5d667
Walz, Christoph
b8d235ac-2a38-41e7-a22f-e0bb78719b19
Frickenhaus, Marie
d72714d3-f173-4b86-993c-bacaa8142d65
Schemionek, Mirle
4f9eec94-bfad-4def-aec5-6f61aaf3ba81
Stehling, Martin
cd1db61d-1ca8-48f3-9cb1-eec1c24a3a28
Serve, Hubert
693c7311-7f0a-4e4a-a925-62e15d3e97fc
Cross, Nicholas C.P.
f87650da-b908-4a34-b31b-d62c5f186fe4
Hochhaus, Andreas
b37b9b7d-85ff-455e-994d-fcc2adf94088
Hofmann, Wolf-Karsten
ab66838b-bf8c-4352-a0f0-3c8aafed2570
Berdel, Wolfgang E.
b7304512-87d2-427d-abb2-b0ec9999cf95
Muller-Tidow, Carsten
51c06b7c-d667-4600-82ee-009623532cdd
Reiter, Andreas
ffa23e84-4a13-4cb5-aaf0-3fafe25dbede
Koschmieder, Steffen
8ae4c754-cb4e-4b21-99ab-a7a423e8a53d
10 March 2011
Elling, Christian
51a03004-8d0b-4f55-addf-54451e648ce0
Erben, Phillipp
ab2de2e7-98f4-495f-add1-00b7e0e5d667
Walz, Christoph
b8d235ac-2a38-41e7-a22f-e0bb78719b19
Frickenhaus, Marie
d72714d3-f173-4b86-993c-bacaa8142d65
Schemionek, Mirle
4f9eec94-bfad-4def-aec5-6f61aaf3ba81
Stehling, Martin
cd1db61d-1ca8-48f3-9cb1-eec1c24a3a28
Serve, Hubert
693c7311-7f0a-4e4a-a925-62e15d3e97fc
Cross, Nicholas C.P.
f87650da-b908-4a34-b31b-d62c5f186fe4
Hochhaus, Andreas
b37b9b7d-85ff-455e-994d-fcc2adf94088
Hofmann, Wolf-Karsten
ab66838b-bf8c-4352-a0f0-3c8aafed2570
Berdel, Wolfgang E.
b7304512-87d2-427d-abb2-b0ec9999cf95
Muller-Tidow, Carsten
51c06b7c-d667-4600-82ee-009623532cdd
Reiter, Andreas
ffa23e84-4a13-4cb5-aaf0-3fafe25dbede
Koschmieder, Steffen
8ae4c754-cb4e-4b21-99ab-a7a423e8a53d
Elling, Christian, Erben, Phillipp, Walz, Christoph, Frickenhaus, Marie, Schemionek, Mirle, Stehling, Martin, Serve, Hubert, Cross, Nicholas C.P., Hochhaus, Andreas, Hofmann, Wolf-Karsten, Berdel, Wolfgang E., Muller-Tidow, Carsten, Reiter, Andreas and Koschmieder, Steffen
(2011)
Novel imatinib-sensitive PDGFRA activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.
Blood, 117 (10), .
(doi:10.1182/blood-2010-05-286757).
(PMID:21224473)
Abstract
The FIP1L1-PDGFRA fusion is seen in a fraction of cases with a presumptive diagnosis of hypereosinophilic syndrome (HES). However, since most HES patients lack FIP1L1-PDGFRA, we studied whether they harbor activating mutations of the PDGFRA gene. Sequencing of 87 FIP1L1-PDGFRA negative HES patients revealed several novel PDGFRA point mutations (R481G, L507P, I562M, H570R, H650Q, N659S, L705P, R748G, and Y849S). When cloned into 32D cells, N659S and Y849S and, upon selection for high expressors, also H650Q and R748G mutants induced growth factor-independent proliferation, clonogenic growth, and constitutive phosphorylation of PDGFRA and STAT5. Imatinib antagonized STAT5 phosphorylation. Mutations involving positions 659 and 849 had been shown previously to possess transforming potential in gastrointestinal stromal tumors. Since H650Q and R748G mutants possessed only weak transforming activity, we injected 32D cells harboring these mutants or FIP1L1-PDGFRA into mice and found that they induced a leukemia-like disease. Oral imatinib treatment significantly decreased leukemic growth in vivo and prolonged survival. In conclusion, our data provide evidence that imatinib-sensitive PDGFRA point mutations play an important role in the pathogenesis of HES and we propose that more research should be performed to further define the frequency and treatment response of PDGFRA mutations in FIP1L1-PDGFRA negative HES patients
This record has no associated files available for download.
More information
Accepted/In Press date: 11 January 2011
Published date: 10 March 2011
Identifiers
Local EPrints ID: 175285
URI: http://eprints.soton.ac.uk/id/eprint/175285
ISSN: 0006-4971
PURE UUID: 639f947f-58c0-4287-80bb-ef8b341010d1
Catalogue record
Date deposited: 22 Feb 2011 13:25
Last modified: 14 Mar 2024 02:46
Export record
Altmetrics
Contributors
Author:
Christian Elling
Author:
Phillipp Erben
Author:
Christoph Walz
Author:
Marie Frickenhaus
Author:
Mirle Schemionek
Author:
Martin Stehling
Author:
Hubert Serve
Author:
Andreas Hochhaus
Author:
Wolf-Karsten Hofmann
Author:
Wolfgang E. Berdel
Author:
Carsten Muller-Tidow
Author:
Andreas Reiter
Author:
Steffen Koschmieder
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics